Cargando…
Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials
BACKGROUND: The RV144 clinical trial showed for the first time that vaccination could provide modest but significant protection from HIV-1 infection. To understand the protective response, and to improve upon the vaccine's efficacy, it is important to define the structure of the immunogens used...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425498/ https://www.ncbi.nlm.nih.gov/pubmed/22928048 http://dx.doi.org/10.1371/journal.pone.0043903 |